Capital Advisors Ltd’s BioMarin Pharmaceuticals BMRN Stock Holding History

Capital Advisors Ltd’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4K	Buy	+67	New	+$3.67K	﹤0.01%	993
2025 Q3	–	Sell	-158	Closed	-$9K	–	1363
2025 Q2	$9K	Buy	+158	New	+$9.3K	﹤0.01%	809
2025 Q1	–	Sell	-11	Closed	-$1K	–	1352
2024 Q4	$1K	Buy	+11	New	+$737	﹤0.01%	1147
2024 Q2	–	Sell	-5	Closed	–	–	1391
2024 Q1	$0	Buy	5 +1	+25%	+$90	﹤0.01%	1364
2023 Q4	$0	Sell	4 -1	-20%	-$88	﹤0.01%	1301
2023 Q3	$0	Sell	5 -2	-29%	-$178	﹤0.01%	1294
2023 Q2	$1K	Hold	7	–	–	﹤0.01%	1094
2023 Q1	$1K	Hold	7	–	–	﹤0.01%	990
2022 Q4	$1K	Sell	7 -9	-56%	-$845	﹤0.01%	951
2022 Q3	$1K	Buy	+16	New	+$1.43K	﹤0.01%	966
2022 Q1	–	Sell	-1	Closed	–	–	921
2021 Q4	$0	Buy	+1	New	+$83	﹤0.01%	819

Other funds holding BMRN

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Covea Finance Paris, France $3.17B AUM 35.01% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

SAM

Secure Asset Management Troy, Michigan $714M AUM 27.91% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

Capital Advisors Ltd's BMRN Position: Q2 2026 in Review

Capital Advisors Ltd opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 67 shares worth $4K. The stake represents ﹤0.01% of the portfolio and ranks #993 among its holdings. This is a return to the name: Capital Advisors Ltd previously reported a position in BMRN as recently as Q2 2025.

Capital Advisors Ltd first reported a position in BMRN in Q4 2021 and has held it in 11 quarters since. The position peaked at $9K in Q2 2025. 57 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Capital Advisors Ltd held 67 shares of BioMarin Pharmaceuticals worth $4K as of Q2 2026.
BioMarin Pharmaceuticals was a new Capital Advisors Ltd position in Q2 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q2 2026, its #993 holding.
Capital Advisors Ltd first reported a position in BioMarin Pharmaceuticals in Q4 2021 and has held it in 11 quarters since.
Capital Advisors Ltd's BioMarin Pharmaceuticals position peaked at $9K in Q2 2025.
57 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.